Zenith Capital (Zenith Capital) Purchase Of Business : $ Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Purchase Of Business?

Zenith Capital's purchase of business for the three months ended in . 20 was $0.00 Mil. It means Zenith Capital spent $0.00 Mil on purchasing business.

Compared with last quarter ($0.00 Mil in . 20 ), Zenith Capital spent the same money on purchasing business in . 20 ($0.00 Mil).

Zenith Capital Purchase Of Business Historical Data

The historical data trend for Zenith Capital's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Purchase Of Business Chart

Zenith Capital Annual Data

Trend

Purchase Of Business

Zenith Capital Quarterly Data

Purchase Of Business

Zenith Capital Purchase Of Business Calculation

The amount used to purchase business.

Zenith Capital Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Purchase Of Business

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines